MetaVia to present DA-1726 dual-agonist and vanoglipel data at Feb. 25 briefing

Cambridge biotech schedules data briefing ahead of Emerging Growth Conference

MetaVia Inc. says its chief executive and chief financial officer will present an update on the company’s obesity and metabolic therapy programs at the Emerging Growth Conference on Feb. 25, 2026. The company is flagging new clinical and translational data that executives plan to discuss during a 10:15 a.m. ET presentation followed by a live question-and-answer session.

DA-1726 is centrepiece of upcoming presentation

MetaVia focuses its presentation on DA-1726, an oxyntomodulin analogue that acts as a dual glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist. The company says the mechanism is designed to reduce food intake while increasing energy expenditure, and highlights Phase 1 multiple ascending dose (MAD) trial results that it characterises as showing “best-in-class” potential for weight loss, improved glucose control and waist circumference reduction. Executives are expected to outline the MAD trial’s safety and tolerability findings and discuss next steps for clinical development and dose optimisation.

Analysts and attendees will also listen for context on how DA-1726’s dual-agonist profile compares with existing GLP-1–centric therapies and other multi-receptor approaches in obesity, including any planned combination strategies or biomarkers MetaVia intends to use in later-stage trials. The presentation is likely to address regulatory and enrolment timelines as the company advances toward larger efficacy studies, and to provide detail on patient populations targeted for pivotal trials.

Vanoglipel and liver-targeted activity to feature briefly

MetaVia also plans to update on vanoglipel (DA-1241), a G-protein-coupled receptor 119 (GPR119) agonist that stimulates release of gut peptides GLP-1, GIP and PYY. The company notes preclinical data showing improvements in hepatic inflammation, lipid metabolism, fibrosis and glucose control, and says a Phase 2a study demonstrates direct hepatic action alongside glucose-lowering effects.

Registration for the conference presentation is available via the event link and attendees may submit advance questions by email. MetaVia provides corporate contact information and a website for further details and to arrange one-on-one meetings with management.